DuPont Merck Pharmaceutical Co. v. Superior Court

92 Cal. Rptr. 2d 755, 78 Cal. App. 4th 562
CourtCalifornia Court of Appeal
DecidedFebruary 14, 2000
DocketG024013
StatusPublished
Cited by103 cases

This text of 92 Cal. Rptr. 2d 755 (DuPont Merck Pharmaceutical Co. v. Superior Court) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DuPont Merck Pharmaceutical Co. v. Superior Court, 92 Cal. Rptr. 2d 755, 78 Cal. App. 4th 562 (Cal. Ct. App. 2000).

Opinion

*564 Opinion

RYLAARSDAM, J.

The complaint in this class action suit alleges defendant made false statements before regulatory bodies, the medical profession, and to the public in connection with one of its pharmaceutical products. The trial court denied a motion to strike under the anti-SLAPP (strategic lawsuit against public participation) statute. (Code Civ. Proc., § 425.16; all further statutory references are to this code, unless otherwise indicated.) The court’s decision was based on a determination that the allegations of the complaint did not fit the requirement of the statute that the causes of action arose from acts of defendant “in furtherance of [defendant’s] right of petition or- free speech under the United States or California Constitution in connection with a public issue.” (§ 425.16, subd. (b)(1).)

Since we conclude the acts with which the complaint charges defendant qualify under the first step of the SLAPP analysis, we remand the case to the trial court to make a determination whether plaintiffs can establish a probability they will prevail. This latter determination cannot be based on allegations but must be based on evidence, and if it results in a judgment striking the complaint, should be supported by a statement of decision.

Facts

Plaintiffs’ purported class action seeks damages on behalf of the purchasers of the drug Coumadin (genetically, warfarin sodium), a prescription drug used to thin blood. The complaint alleges defendant, the manufacturer of Coumadin, artificially inflated the price of the drug by “disseminating false and omissive information concerning the use and effectiveness” of an equivalent generic product. The first amended complaint asserts causes of action under the California Consumers Legal Remedies Act (Civ. Code, § 1750 et seq.) and the California Unfair Practices Act. (Bus. & Prof. Code, § 17500.)

The acts attributed to defendant upon which these causes of action are based consist of allegations defendant: (1) “took measures to prevent and/or delay Food and Drug Administration (‘FDA’) approval of warfarin sodium in a generic form, [(2)] published and disseminated false and misleading information to the public regarding the generic form of warfarin sodium, and [(3)] undertook aggressive lobbying and public relations efforts, involving the dissemination of false and misleading information, and increased its marketing efforts about Coumadin directed to doctors and other medical professionals.” Plaintiffs further allege defendant: (4) “published and disseminated false and misleading information in, inter alia press releases, *565 Internet bulletins and public statements . . . and [(5)] initiated an effort to delay the introduction of a generic version of Coumadin by [filing] a petition with the FDA for the change in [the bioequivalence] standard.” Plaintiffs further complain defendant (6) “sought legislation in at least 20 states that would increase the requirements for substitution of [the] generic version of warfarin sodium for Coumadin.” Finally, they allege that defendant (7) “instituted an initiative to entrench doctor’s prescribing habits . . . through the dissemination of false and misleading information about the proposed generic version of Coumadin.”

Defendant demurred to the first amended complaint and, at the same time, filed a motion to strike under the anti-SLAPP suit statute. (§ 425.16.) The trial court overruled the demurrer and denied the motion.

Defendant then petitioned this court for a writ of mandate compelling the trial court to grant its motion to strike. Because section 425.16, subdivision (f) requires a motion under the statute to be filed within 60 days of serving the complaint, absent special permission by the court, and because the record supplied to us failed to demonstrate permission was sought or obtained, we denied the petition summarily. Defendant then petitioned the California Supreme Court for review. That court granted review and transferred the matter to this court with directions to vacate the order denying mandate, to issue an alternative writ, and to consider this matter in light of Briggs v. Eden Council for Hope and Opportunity (1999) 19 Cal.4th 1106 [81 Cal.Rptr.2d 471, 969 P.2d 564], We interpreted the order of the Supreme Court to require us to consider the matter on the merits. We thereupon issued an alternative writ and established a further briefing schedule.

Discussion

Acts in Furtherance of Right of Petition or Free Speech?

Section 425.16, subdivision (b)(1) provides for a motion to strike “[a] cause of action against a person arising from any act of that person in furtherance of the person’s right of petition or free speech under the United States or California Constitution in connection with a public issue . . . unless the court determines that the plaintiff has established that there is a probability that the plaintiff will prevail on the claim.” We must therefore first consider whether the complaint alleges acts in furtherance of defendant’s right of petition or free speech in connection with a public issue.

The seven acts or groups of acts alleged in the amended complaint which we list above may be summarized as falling into two categories: (1) lobbying *566 and other activities seeking to influence the decisions of regulatory and legislative bodies and (2) advertising, marketing, and public relations activities directed at the medical profession and the general public. The antiSLAPP statute provides that the phrase “ ‘act in furtherance of a person’s right of petition or free speech under the United States or California Constitution in connection with a public issue’ includes: (1) any written or oral statement or writing made before a legislative, executive, or judicial proceeding, or any other official proceeding authorized by law.” (§ 425.16, subd. (e)(1).) Defendant’s lobbying and other activities seeking to influence the decisions of regulatory and legislative bodies fall within this definition. By failing to argue the contrary, plaintiffs concede this issue.

Plaintiffs argue the alleged advertising, marketing, and public relations activities do not fall within the protections of the First Amendment’s right to freedom of speech. The first amended complaint alleges defendant’s statements were false and misleading. Citing Zauderer v. Office of Disciplinary Counsel (1985) 471 U.S. 626, 637-638 [105 S.Ct. 2265, 2274-2275, 85 L.Ed.2d 652], and Bill Johnson's Restaurants, Inc. v. NLRB (1983) 461 U.S. 731, 743 [103 S.Ct. 2161, 2170, 76 L.Ed.2d. 277], plaintiffs contend that false, deceptive, and misleading statements are not protected by the right of free speech. This may be true, at least as far as false advertising is concerned. However, in making this argument, plaintiffs are placing the cart before the horse. The allegation in the unverified complaint that the statements were false may or may not be true.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Solorzano v. Mavenform CA1/2
California Court of Appeal, 2025
People v. Stewart CA2/4
California Court of Appeal, 2025
Blatz v. MLG CA4/3
California Court of Appeal, 2024
Clean Up America v. City of L.A. CA2/8
California Court of Appeal, 2023
Bleckman v. Katzenbach CA2/2
California Court of Appeal, 2021
Medical Marijuana, Inc. v. ProjectCBD.com
California Court of Appeal, 2020
Issa v. Applegate
242 Cal. Rptr. 3d 809 (California Court of Appeals, 5th District, 2019)
Area 51 Productions v. City of Alameda
California Court of Appeal, 2018
Industrial Waste & Debris Box Service, Inc. v. Murphy
4 Cal. App. 5th 1135 (California Court of Appeal, 2016)
Gonzalez v. Burtech Pipeline CA4/2
California Court of Appeal, 2016
Schelske v. TMZ Productions CA2/2
California Court of Appeal, 2016
Chang-Mathieu v. Larner CA2/2
California Court of Appeal, 2016
Nobles v. Karaka CA2/3
California Court of Appeal, 2016
Calande v. Surf and Sand CA6
California Court of Appeal, 2015
Mobilitie v. Lodder CA4/3
California Court of Appeal, 2015
Pinnock v. Gotti CA4/1
California Court of Appeal, 2015
Collier v. Harris
240 Cal. App. 4th 41 (California Court of Appeal, 2015)
White v. Maksimow CA4/1
California Court of Appeal, 2015

Cite This Page — Counsel Stack

Bluebook (online)
92 Cal. Rptr. 2d 755, 78 Cal. App. 4th 562, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dupont-merck-pharmaceutical-co-v-superior-court-calctapp-2000.